Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jun 16;13(5):787–796. doi: 10.1111/acel.12220

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published 2014. This article is a U.S. Government work and is in the public domain in the USA.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Short-term SRT2104 treatment preserves muscle and bone mass. (A) Bodyweights during 14 days of hindlimb suspension and average food consumption (inset) for 6-month-old mice fed either a standard diet (SD) or SD supplemented with SRT2104 for 6 weeks. (B) Muscle weights. (C) Trabecular bone volume, trabecular connectivity, and trabecular bone mineral density (BMD). (D) Alkaline phosphatase (AP) activity in C2C12 cells infected with SIRT1 shRNA or nontargeting shRNA control and treated with 1 and 3 μm SRT2104 for 24 h. (E) Osteoclast (OC) number in bone marrow-derived osteoblastic cells from wild-type (WT) mice and SIRT1^f/f mice and treated with 1 and 3 μm SRT2104 for 4 days. (F) Cortical thickness in femurs from wild-type (WT) and SIRT1KO mice. Data are mean ± SEM. *P < 0.05. SOL, soleus; PL, plantaris; GAS, gastrocnemius; BV, bone volume; TV, total volume; Tb, trabecular.